• Touyun Biotech guided for HK$ 180 million to HK$ 200 million profit attributable to owners for the six months ended June 30, 2026.
• That implies a 1,025% to 1,150% jump from about HK$ 16 million in the prior-year period.
• Outlook driven mainly by about HK$ 340 million fair value gain on financial assets at fair value through profit or loss.
• Comparable fair value gain was about HK$ 73 million in the six months ended June 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Touyun Biotech Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300106), on August 26, 2026, and is solely responsible for the information contained therein.